Rifampin NDC 62135-315

NDC codes

FDA NDC Directory

Product NDC (as listed)62135-315Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62135-0315Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62135-315-30	62135031530	30 CAPSULE in 1 BOTTLE (62135-315-30)Marketed from Apr 5, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Rifampin
Generic name (nonproprietary): rifampin
Active ingredients: Rifampin — 150 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Chartwell RX, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 065390
Marketing start: Apr 20, 2008
Listing expires: Dec 31, 2026
Other FDA classes: Rifamycins (Chemical structure)
Identifiers: Product ID 62135-315_f9244302-8654-6016-e053-6294a90ad64cSPL ID f9244302-8654-6016-e053-6294a90ad64cSPL set ID 4c39ee75-ae96-456d-bf47-16d49865345eRxCUI 198201, 198202UNII VJT6J7R4TRUPC 0362135315306, 0362135316600
Pharmacologic class: Rifamycin Antibacterial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N462135031530 followed by a unit qualifier and the quantity

Package 62135-0315-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 12, 2023.

Indications (excerpt from the label)

INDICATIONS AND USAGE In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. If test results show resistance to rifampin and the patient is not responding to therapy, the drug regim…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 065390

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 065390
Product	Strength	Form · route	Labeler	Product NDC
Rifampin	Rifampin 300 mg/1	CapsuleOral	Chartwell RX, LLC	62135-316